Price$3.72-1.79 (-32.49%)
2026-01-282026-05-01
News · 26 weeks44-20%
2025-11-022026-04-26
Mix2190d
- SEC Filings8(38%)
- Other6(29%)
- Insider6(29%)
- Leadership1(5%)
Latest news
25 items- SECCervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - CervoMed Inc. (0001053691) (Filer)
- PRCervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy BodiesResults consistent with pre-clinical studies demonstrating that, in the early stages of the neurodegenerative process, disease progression in the basal forebrain is reversible Findings also correlate with previously reported results on neflamapimod's observed effects on a blood biomarker of neurodegenerative disease activity, providing additional evidence of neflamapimod's potential to act on the underlying disease process in dementia with Lewy Bodies (DLB) DLB is the second most common progressive dementia, affecting millions worldwide, and has no approved treatments in the United States or European Union BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Today at the 2026 AAN Annual Meeting i
- SECCervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - CervoMed Inc. (0001053691) (Filer)
- PRCervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual MeetingUpdate will include new MRI analyses from the Phase 2b RewinD-LB clinical trial, status of global regulatory discussions, and finalized Phase 3 trial design Additional data from MRI analyses will also be featured at 2026 American Academy of Neurology Annual Meeting later this month; findings demonstrate neflamapimod's potential positive impact on basal forebrain atrophy and functional connectivity Dementia with Lewy bodies (DLB) is the second most common progressive dementia, affecting millions worldwide, and has no approved treatments in the United States or European Union BOSTON, April 07, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO) (CervoMed or the Company), a clinical-sta
- SECCervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - CervoMed Inc. (0001053691) (Filer)
- SECCervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - CervoMed Inc. (0001053691) (Filer)
- PRCervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod's Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer's Disease Co-PathologyNew analyses show DLB patients with lower plasma pTau181 levels — indicating an earlier stage of disease and absence of Alzheimer's disease (AD) co-pathology — experienced greater clinical benefit with neflamapimod in Phase 2b clinical trial PK/PD analyses of Phase 2b clinical data provide further insight into the drug plasma concentration levels of neflamapimod associated with a clinical effect Findings further support neflamapimod's potential to target the underlying cause of disease in DLB and the Company's patient enrichment strategy and dosing regimen for planned Phase 3 trial BOSTON, March 19, 2026 (GLOBE NEWSWIRE) -- This week, in an oral session at the AD/PD™ 2026 Conference in
- SECCervoMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - CervoMed Inc. (0001053691) (Filer)
- SECSEC Form 10-K filed by CervoMed Inc.10-K - CervoMed Inc. (0001053691) (Filer)
- PRCervoMed to Participate in Upcoming Investor ConferencesBOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that Company management will participate in the following investor conferences during the month of March: Leerink Global Healthcare Conference Format: 1x1 Investor MeetingsDate: Wednesday, March 11, 2026 38th Annual ROTH ConferenceFormat: Fireside Chat & 1x1 Investor MeetingsPresentation Date: Monday, March 23, 2026Presentation Time: 12:00 – 12:30 PM PT The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https://ir.cervomed.com/news-events/events-and-presentati
- SECCervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - CervoMed Inc. (0001053691) (Filer)
- PRCervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy BodiesBioavailability data recently obtained from Phase 1 study with a stable crystal form of neflamapimod manufactured using a new, controlled manufacturing process Pharmacokinetic profile of the new, stable crystal form of neflamapimod largely overlaps with the therapeutically active drug product used in Phase 2b trial extension To ensure that plasma drug concentrations associated with therapeutic activity are achieved, dosing regimen in the planned Phase 3 trial in dementia with Lewy bodies will be 50mg TID of the stable, crystal form of neflamapimod BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (CervoMed or the Company) (NASDAQ:CRVO), a clinical-stage biotechnology company dev
- SECCervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - CervoMed Inc. (0001053691) (Filer)
- PRCERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of DirectorsSOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, announces the appointment of Eric Francois to the Company's Board of Directors. "Eric's decades of financial, transactional and operational experience will make an immediate impact to CERo's board of directors," said Chris Ehrlich, Company Chairman and Chief Executive Officer. "Furthermore, his expertise in capital raising, M&A, and business development will be an impactful addition at this stage of our development." Mr. Francois is an executive with over 25
- INSIDERSEC Form 4 filed by Chief Commercial and Business Winton Matthew4 - CervoMed Inc. (0001053691) (Issuer)
- INSIDERSEC Form 4 filed by Director Gregoire Sylvie4 - CervoMed Inc. (0001053691) (Issuer)
- INSIDERSEC Form 4 filed by CFO, GC & Secretary Elder William Robert4 - CervoMed Inc. (0001053691) (Issuer)
- INSIDERSEC Form 4 filed by EVP, RA and GA and PgM De Rosch Mark4 - CervoMed Inc. (0001053691) (Issuer)
- INSIDERSEC Form 4 filed by CEO & President Alam John J4 - CervoMed Inc. (0001053691) (Issuer)
- INSIDERSEC Form 4 filed by EVP, Clinical Development Blackburn Kelly4 - CervoMed Inc. (0001053691) (Issuer)
- SECSEC Form SCHEDULE 13G filed by CervoMed Inc.SCHEDULE 13G - CervoMed Inc. (0001053691) (Subject)
- SECCervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - CervoMed Inc. (0001053691) (Filer)
- ANALYSTCantor Fitzgerald initiated coverage on CervoMedCantor Fitzgerald initiated coverage of CervoMed with a rating of Overweight
- INSIDERSEC Form 4 filed by Director Quigley David4 - CervoMed Inc. (0001053691) (Issuer)
- INSIDERSEC Form 3 filed by new insider Quigley David3 - CervoMed Inc. (0001053691) (Issuer)
CRVO FAQ
5 questionsWhere does CRVO stock trade?
CervoMed Inc. (CRVO) is listed on NASDAQ.What sector and industry is CRVO in?
CervoMed Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about CRVO?
CervoMed Inc. has had 8 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight on 2025-12-18. Recent price targets range from $1400.00 to $4500.00.What companies are similar to CRVO?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare CRVO side-by-side with any of them on Quantisnow.How can I track CRVO on Quantisnow?
Quantisnow aggregates CervoMed Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CRVO to receive live email and push alerts on every new disclosure.